Aurobindo Antibiotics Private Limited, a active private limited company, was established on 06 October 2020 in Vishakhapatnam, Andhra Pradesh, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24110AP2020PTC115965. Registered under ROC Roc Vijayawada. it is unlisted. It has an authorized capital of ₹1.00 Cr and a paid-up capital of ₹1.00 Cr.
Employing 1 professional, Its leadership includes Sadananda Reddy Sannareddy (Director), Nityananda Reddy Kambam (Director), Gopala Krishna Reddy Penupolu (Director). Past directors included Nityananda Reddy Kambam. Its latest AGM occurred on 22 September 2025, with the balance sheet filed on 31 March 2025. It is based at Unit 14, Jn Pharma City, Plot No 17, Rno.10, 11 & 19, 20, E Bonangi Vlg,, Vishakhapatnam, Andhra Pradesh, 531021.
U24110AP2020PTC115965
115965
06 October 2020
₹1.00 Cr
₹1.00 Cr
Roc Vijayawada
Unlisted
Active
Explore comprehensive insights into Aurobindo Antibiotics Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sadananda Reddy Sannareddy | Director | 06 Oct 2020 | Current |
| Nityananda Reddy Kambam | Director | 26 Dec 2022 | Current |
| Gopala Krishna Reddy Penupolu | Director | 06 Oct 2020 | Current |
| Bhanu Murthy Chavali | Director | 06 Oct 2020 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 24 Jul 2023 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Aurobindo Antibiotics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 46.53% increase in profit. The company's net worth dipped by a decrease of 3.11%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Aurobindo Antibiotics had a promoter holding of 100.00%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Aurobindo Antibiotics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Aurobindo Antibiotics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aurobindo Antibiotics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Aurobindo Antibiotics Private Limited last Annual general meeting of members was held on 22 Sep 2025 as per latest MCA records. was documented.
Aurobindo Antibiotics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Vijayawada. was recorded as a recent event.
Nityananda Reddy Kambam was appointed as a Director was appointed as a Director on 26 Dec 2022 & has been associated with this company since 2 years 11 months . was recorded as a recent event.
Sadananda Reddy Sannareddy was appointed as a Director was appointed as a Director on 06 Oct 2020 & has been associated with this company since 5 years 1 month . was recorded as a recent event.
Gopala Krishna Reddy Penupolu was appointed as a Director was appointed as a Director on 06 Oct 2020 & has been associated with this company since 5 years 1 month . was recorded as a recent event.
Progress on Bhanu Murthy Chavali was appointed as a Director was appointed as a Director on 06 Oct 2020 & has been associated with this company since 5 years 1 month . was documented.
FDA: Aurobindo Pharma's manufacturing facility has incomplete and misleading documents. They also found issues with quality control and training. Equipment is not cleaned properly. Aurobindo says they will fix it. FDA inspected from Sept 19-27 and issued warning letter for other facility. Aurobindo's stock went down..
The CIN of Aurobindo Antibiotics Private Limited is U24110AP2020PTC115965.
Aurobindo Antibiotics Private Limited is headquartered at Unit 14, Jn Pharma City, Plot No 17, Rno.10, 11 & 19, 20, E Bonangi Vlg,, Vishakhapatnam, Andhra Pradesh, 531021.
Aurobindo Antibiotics Private Limited was incorporated on 06 October 2020.
The current directors of Aurobindo Antibiotics Private Limited are
The primary industry of Aurobindo Antibiotics Private Limited is Manufacturing.
Aurobindo Antibiotics Private Limited is unlisted.
The authorized capital of Aurobindo Antibiotics Private Limited is ₹1.00 Cr, and the paid-up capital is ₹1.00 Cr.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX